BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 24491303)

  • 1. KRAS and cancer stem cells in APC-mutant colorectal cancer.
    Fearon ER; Wicha MS
    J Natl Cancer Inst; 2014 Feb; 106(2):djt444. PubMed ID: 24491303
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/β-catenin signaling.
    Cristóbal I; Rincón R; Manso R; Rojo F; García-Foncillas J
    J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25136032
    [No Abstract]   [Full Text] [Related]  

  • 3. Response.
    Moon BS; Cho YH; Jeong WJ; Choi KY
    J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25136033
    [No Abstract]   [Full Text] [Related]  

  • 4. Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/β-catenin signaling.
    Moon BS; Jeong WJ; Park J; Kim TI; Min do S; Choi KY
    J Natl Cancer Inst; 2014 Feb; 106(2):djt373. PubMed ID: 24491301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of the Wnt/β-catenin and RAS-ERK pathways involving co-stabilization of both β-catenin and RAS plays important roles in the colorectal tumorigenesis.
    Lee SK; Hwang JH; Choi KY
    Adv Biol Regul; 2018 May; 68():46-54. PubMed ID: 29449169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression.
    Janssen KP; Alberici P; Fsihi H; Gaspar C; Breukel C; Franken P; Rosty C; Abal M; El Marjou F; Smits R; Louvard D; Fodde R; Robine S
    Gastroenterology; 2006 Oct; 131(4):1096-109. PubMed ID: 17030180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for possible non-canonical pathway(s) driven early-onset colorectal cancer in India.
    Raman R; Kotapalli V; Adduri R; Gowrishankar S; Bashyam L; Chaudhary A; Vamsy M; Patnaik S; Srinivasulu M; Sastry R; Rao S; Vasala A; Kalidindi N; Pollack J; Murthy S; Bashyam M
    Mol Carcinog; 2014 Feb; 53 Suppl 1(0 1):E181-6. PubMed ID: 23168910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A mutant KRAS-induced factor REG4 promotes cancer stem cell properties via Wnt/β-catenin signaling.
    Hwang JH; Yoon J; Cho YH; Cha PH; Park JC; Choi KY
    Int J Cancer; 2020 May; 146(10):2877-2890. PubMed ID: 31605540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic KRAS is not necessary for Wnt signalling activation in APC-associated FAP adenomas.
    Obrador-Hevia A; Chin SF; González S; Rees J; Vilardell F; Greenson JK; Cordero D; Moreno V; Caldas C; Capellá G
    J Pathol; 2010 May; 221(1):57-67. PubMed ID: 20196079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Setting future standards for KRAS testing in colorectal cancer.
    van Krieken H; Tol J
    Pharmacogenomics; 2009 Jan; 10(1):1-3. PubMed ID: 19102707
    [No Abstract]   [Full Text] [Related]  

  • 11. Wnt and Kras signaling-dark siblings in lung cancer.
    Pacheco-Pinedo EC; Morrisey EE
    Oncotarget; 2011 Jul; 2(7):569-74. PubMed ID: 21753228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS mutations in primary and metastatic colorectal cancer.
    Han CB; Li F; Ma JT; Zou HW
    Int J Colorectal Dis; 2013 May; 28(5):731-2. PubMed ID: 22744738
    [No Abstract]   [Full Text] [Related]  

  • 13. Novel multiple, monoallelic KRAS mutations at codon 12 and 13.
    Keller G; Geist B; Slotta-Huspenina J; Langer R; Nagl F; Fend F; Höfler H; Perren A
    Int J Cancer; 2009 Dec; 125(11):2744-5. PubMed ID: 19521964
    [No Abstract]   [Full Text] [Related]  

  • 14. Stromal cells do not share KRAS mutations that the epithelial component harbors in colorectal carcinomas.
    Baloglu H; Yigit N
    Cancer Lett; 2011 Sep; 308(1):118-21. PubMed ID: 21624768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2.
    Mologni L; Dekhil H; Ceccon M; Purgante S; Lan C; Cleris L; Magistroni V; Formelli F; Gambacorti-Passerini CB
    Cancer Res; 2010 Sep; 70(18):7253-63. PubMed ID: 20823162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Stem cell theory of colorectal cancer and its connection with molecular-biological data].
    Hagymási K; Molnár B; Sipos F; Galamb O; Tulassay Z
    Orv Hetil; 2007 Apr; 148(17):779-85. PubMed ID: 17452307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. β-Catenin-RAS interaction serves as a molecular switch for RAS degradation via GSK3β.
    Lee SK; Jeong WJ; Cho YH; Cha PH; Yoon JS; Ro EJ; Choi S; Oh JM; Heo Y; Kim H; Min DS; Han G; Lee W; Choi KY
    EMBO Rep; 2018 Dec; 19(12):. PubMed ID: 30413483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of KRAS and BRAF gene mutations on targeted therapies in colorectal cancer.
    Bass A
    J Clin Oncol; 2011 Jul; 29(19):2728-9. PubMed ID: 21646605
    [No Abstract]   [Full Text] [Related]  

  • 19. [Clinical significance and the handling of KRAS testing on metastatic colorectal cancer].
    Kawamoto Y; Yoshino T
    Nihon Rinsho; 2011 Apr; 69 Suppl 3():346-50. PubMed ID: 22213982
    [No Abstract]   [Full Text] [Related]  

  • 20. LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo.
    Zhou J; Zheng B; Ji J; Shen F; Min H; Liu B; Wu J; Zhang S
    Tumour Biol; 2015 May; 36(5):3301-8. PubMed ID: 25524577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.